Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "De Luca, Giuseppe (55586620900)"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Cardiovascular disease and COVID-19: A consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)
    (2021)
    Cenko, Edina (55651505300)
    ;
    Badimon, Lina (7102141956)
    ;
    Bugiardini, Raffaele (26541113500)
    ;
    Claeys, Marc J (7102514922)
    ;
    De Luca, Giuseppe (55586620900)
    ;
    De Wit, Cor (7005808759)
    ;
    Derumeaux, Geneviève (55699348000)
    ;
    Dorobantu, Maria (6604055561)
    ;
    Duncker, Dirk J (7005277014)
    ;
    Eringa, Etto C (6507199239)
    ;
    Gorog, Diana A (7003699023)
    ;
    Hassager, Christian (7005846737)
    ;
    Heinzel, Frank R (7005851989)
    ;
    Huber, Kurt (35376715600)
    ;
    Manfrini, Olivia (6505860414)
    ;
    Milicic, Davor (56503365500)
    ;
    Oikonomou, Evangelos (36717891800)
    ;
    Padro, Teresa (6701424923)
    ;
    Trifunovic-Zamaklar, Danijela (9241771000)
    ;
    Vasiljevic-Pokrajcic, Zorana (6602641182)
    ;
    Vavlukis, Marija (14038383200)
    ;
    Vilahur, Gemma (57205093142)
    ;
    Tousoulis, Dimitris (35399054300)
    The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as 'post-acute COVID-19' may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance. © 2021 Published on behalf of the European Society of Cardiology. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'
    (2020)
    Padro, Teresa (6701424923)
    ;
    Manfrini, Olivia (6505860414)
    ;
    Bugiardini, Raffaele (26541113500)
    ;
    Canty, John (7005042319)
    ;
    Cenko, Edina (55651505300)
    ;
    De Luca, Giuseppe (55586620900)
    ;
    Duncker, Dirk J. (7005277014)
    ;
    Eringa, Etto C. (6507199239)
    ;
    Koller, Akos (7102499922)
    ;
    Tousoulis, Dimitris (35399054300)
    ;
    Trifunovic, Danijela (9241771000)
    ;
    Vavlukis, Marija (14038383200)
    ;
    De Wit, Cor (7005808759)
    ;
    Badimon, Lina (7102141956)
    Although myocardial ischaemia usually manifests as a consequence of atherosclerosis-dependent obstructive epicardial coronary artery disease, a significant percentage of patients suffer ischaemic events in the absence of epicardial coronary artery obstruction. Experimental and clinical evidence highlight the abnormalities of the coronary microcirculation as a main cause of myocardial ischaemia in patients with 'normal or near normal' coronary arteries on angiography. Coronary microvascular disturbances have been associated with early stages of atherosclerosis even prior to any angiographic evidence of epicardial coronary stenosis, as well as to other cardiac pathologies such as myocardial hypertrophy and heart failure. The main objectives of the manuscript are (i) to provide updated evidence in our current understanding of the pathophysiological consequences of microvascular dysfunction in the heart; (ii) to report on the current knowledge on the relevance of cardiovascular risk factors and comorbid conditions for microcirculatory dysfunction; and (iii) to evidence the relevance of the clinical consequences of microvascular dysfunction. Highlighting the clinical importance of coronary microvascular dysfunction will open the field for research and the development of novel strategies for intervention will encourage early detection of subclinical disease and will help in the stratification of cardiovascular risk in agreement with the new concept of precision medicine. © 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers
    (2023)
    Antoniades, Charalambos (35412194900)
    ;
    Tousoulis, Dimitris (35399054300)
    ;
    Vavlukis, Marija (14038383200)
    ;
    Fleming, Ingrid (7102053742)
    ;
    Duncker, Dirk J. (7005277014)
    ;
    Eringa, Etto (6507199239)
    ;
    Manfrini, Olivia (6505860414)
    ;
    Antonopoulos, Alexios S. (25931366200)
    ;
    Oikonomou, Evangelos (36717891800)
    ;
    Padró, Teresa (6701424923)
    ;
    Trifunovic-Zamaklar, Danijela (9241771000)
    ;
    De Luca, Giuseppe (55586620900)
    ;
    Guzik, Tomasz (7003467849)
    ;
    Cenko, Edina (55651505300)
    ;
    Djordjevic-Dikic, Ana (57003143600)
    ;
    Crea, Filippo (57213692073)
    Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a consensus definition of PVAT around the coronary arteries, as the AT surrounding the artery up to a distance from its outer wall equal to the luminal diameter of the artery. Special focus is given to the interactions between PVAT and the vascular wall that render PVAT a potential therapeutic target in cardiovascular diseases. This Clinical Consensus Statement also discusses the role of PVAT as a clinically relevant source of diagnostic and prognostic biomarkers of vascular function, which may guide precision medicine in atherosclerosis, hypertension, heart failure, and other cardiovascular diseases. In this article, its role as a ‘biosensor’ of vascular inflammation is highlighted with description of recent imaging technologies that visualize PVAT in clinical practice, allowing non-invasive quantification of coronary inflammation and the related residual cardiovascular inflammatory risk, guiding deployment of therapeutic interventions. Finally, the current and future clinical applicability of artificial intelligence and machine learning technologies is reviewed that integrate PVAT information into prognostic models to provide clinically meaningful information in primary and secondary prevention. © 2023 Oxford University Press. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback